TMS Co., Ltd.
TTSE:4891131.00
JPY
+2.00
(+1.55%)
ISIN
JP3544960002
Return %
Stock
S&P 500
1Y
-13.82
14.20
3Y
-44.49
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Takuro Wakabayashi
- Full Time Employees
- 18
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 1-9, Fuchu-shi Tokyo TY Japan 183-0055
- IPO Date
- Nov 22, 2022
- Website
- tms-japan.co.jp
- Similar Companies
- Business
- TMS Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacture, and marketing of pharmaceuticals, quasi-drugs, drug substances, medical devices, and medical commodities. The company specializes in developing drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme involved in inflammatory responses, with a focus on sEH inhibitors for various inflammatory diseases. Its main pharmaceutical pipeline includes TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener exhibiting prothrombolytic and anti-inflammatory/antioxidative activities that has completed Phase 2a clinical trials for acute ischemic stroke treatment; TMS-008, another SMTP congener under nonclinical development targeting inflammatory complications such as acute kidney injury and cancer cachexia; and TMS-009, a product candidate in preclinical development. The company also actively collaborates with academic institutions such as Hokkaido University, Kanazawa University, and Teikyo University to advance its drug research and identify biomarkers related to renal function. Recently, TMS formed a strategic alliance with Ji Xing Pharmaceuticals Limited to enhance its drug development capabilities. Additionally, the company changed its fiscal year end from February 28 to December 31 to align with global accounting standards. Founded in 2005, TMS Co., Ltd. is headquartered in Fuchu, Japan, and operates primarily within the Japanese pharmaceutical market while advancing its innovative drug candidates through clinical and preclinical stages.